Gene therapy for cystic fibrosis utilizing a replication deficient recombinant adenovirus vector to deliver the human cystic fibrosis transmembrane conductance regulator cDNA to the airways. A phase I study.
D000260:Adenoviruses, Human / Q000235:genetics* / Q000276:immunology; D000328:Adult; D001483:Base Sequence; D001798:Blood Proteins / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use*; D002460:Cell Line; D002985:Clinical Protocols; D015331:Cohort Studies; D003550:Cystic Fibrosis / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D004247:DNA; D018076:DNA, Complementary; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics / Q000276:immunology; D006801:Humans; D008297:Male; D008969:Molecular Sequence Data
D001798:Blood Proteins; C505032:CFTR protein, human; D018076:DNA, Complementary; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D004247:DNA